tbuckley/cabot-search huggingface dataset:
THU0360 Differences in Self-Reported Quality of Care for Knee Osteoarthritis Across Denmark, Norway, Portugal and United Kingdom
Authors: N. Østerås, K. Jordan, B. Clausen, C. Cordeiro, K. Dziedzic, G. Grønhaug, H. Lund, S. Pais, K.B. Hagen
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Adherence to recommendations for osteoarthritis (OA) care can be measured using quality indicators (QI). In previous research differences related to the study design or the QI items make it challenging to directly compare the results. This EULAR funded study is the first that has applied the same set of QI items across four European countries. <h3>Objectives</h3> To assess and compare patient perceived quality of OA management in primary health care in Denmark, Norway, Portugal, and the United Kingdom. <h3>Methods</h3> Participants consulting general practitioners with clinical signs and symptoms of knee OA were identified in 30 general practices and invited to complete a cross-sectional survey including 14 QIs for OA care. A QI was considered as eligible if the participant had checked "Yes" or "No", and as achieved if the participant had checked "Yes" to the indicator. The median percentage of eligible QIs achieved by country was determined and compared using negative binomial regression analyses. Achievement of individual QIs by country was determined and compared using logistic regression analyses. <h3>Results</h3> A total of 354 participants self-reported QI achievement. For the total sample, the median percentage of QIs achieved (checked 'Yes') was 48% (IQR 28% to 64%; range 0-100%). By country, the median percentage of QIs achieved was relatively similar across three of the countries, but significantly lower in Denmark (23%) compared to Norway (50%) even after adjustment for age, gender, BMI and comorbidity (rate ratio 0.49; 0.39, 0.62). For individual QIs related to different aspects of OA care, significant differences in self-reported achievement rates between the four countries were seen (Table 1). Achievement rates on individual QIs showed a large variation ranging from 0% ("referral to services for losing weight" &amp; "functional assessments" in Denmark) to 83% ("information about the importance of exercise" in Norway). Compared to Norway, the achievement rates were significantly lower for 10 QIs in Denmark, 2 QIs in Portugal and 1 QI in the UK, whereas UK had significantly higher achievement rates than Norway for 5 QIs. <h3>Conclusions</h3> The results revealed a potential for improvement in OA care in all four countries, but for somewhat different aspects of OA care. By exploring these differences and comparing health care services across countries, ideas may be generated on how the quality of OA care might be improved. Larger studies are needed to confirm and further explore the findings in this study. <h3>Disclosure of Interest</h3> None declared
Frequency of Vaccine-Related and Therapeutic Injections--Romania, 1998
Journal: JAMA (1999)

In Romania therapeutic injections have been associated with transmission of hepatitis B and C viruses HIV type 1 and other blood borne pathogens.  In view of this the Romanian local health department surveyed the districts of Hunedora Lasi Mures and Prahova to estimate the frequency of therapeutic injections and to describe the attitudes and practices of adults about injections to administer medications.  This paper summarizes results from these surveys.  The survey comprised a cluster sample of 300 households in each of the four viral hepatitis sentinel surveillance districts totaling 1200 households.  Overall findings revealed that a substantial proportion of adults preferred injected medication for treatment of conditions for which injections generally are not indicated including fever acute upper respiratory tract infection vitamin supplementation and diarrhea.  However this proportion did not exceed 42% and suggests that Romanians may not insist on injectable medications for common illnesses.  74% of the respondents believed injectable medications were stronger than oral medications.  In addition to patient preference for injections physicians prescribing practices also might affect the observed high use of therapeutic injections.
A multicentric prospective study of intensive induction chemotherapy (API-AI) in localized osteosarcoma patients: Results of a phase II trial coordinated by the French Sarcoma Group (FSG) and the FNCLCC BECT
Authors: S. Piperno-Neumann, B. Bui, J. Blay, H. Roché, F. Pichon, A. Peny, B. Duclos, M. Jimenez, D. Perol, A. Le Cesne
Journal: Journal of Clinical Oncology (2006)

9521 Background: Based on the severe toxicity of high dose methotrexate (MTX) in adult patients, an alternative intensive chemotherapy (CT) was designed, associating doxorubicin, cisplatinum and ifosfamide in API-AI regimen. Promising results in 32 patients in a single institution study (Le Cesne ASCO 2004) led to a national multicenter phase II trial coordinated by the FSG of FNCLCC. Methods: Patients with a localized operable osteosarcoma were eligible. API-AI regimen consisted in 2 cycles every 28 days of doxorubicin 60 mg/m 2 d1 and d15, cisplatinum 100 mg/m 2 d1 and ifosfamide 5g/m 2 d2 and d15, with equivalent dose of mesna and lenograstim after each course for 7 days. Good responders ≥95% necrosis (GR) received 2 postoperative API courses, and poor responders &lt;95% necrosis (PR) a salvage regimen of 3 cycles of etoposide 100 mg/m 2 d1 to d3 and ifosfamide 4 g/m 2 d1 to d3. Results: From March 2001 to January 2004, 43 patients (male/female 28/15) with a median age of 23 years (range 17–50), were included. The median tumor size was 88 mm (13–280). All 43 patients received the preoperative API-AI regimen, with a dose intensity of ≥ 89% of the planned protocol. Toxicity was mainly haematological, with grade 3–4 sepsis, grade 4 neutropenia and thrombocytopenia observed in 12%, 79% and 49% of patients respectively. There was no severe renal and cardiac toxicity. All but 5 patients had a limb sparing surgery performed 77 days (median) after the first cycle (range 56–114 days). Intent to treat analysis showed 16/43 GR (37%). With a median follow-up of 36 months (25–48), the 2 year event-free and overall survival were 74% and 86% respectively. Conclusions: Despite the haematological toxicities, these results compare favorably with other previous induction CT schedules containing MTX in adults. A longer follow-up is required to evaluate the impact of this regimen on overall survival. No significant financial relationships to disclose.
Molecular Sensitization Pattern Profile in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Vs Proton Pump Inhibitor-Nonresponsive Eosinophilic Esophagitis (EoE) in Adult Patients
Authors: Marina Lluncor, Maria Pedrosa, Nataly Cancelliere, Daniela Rivero, Aurora Burgos, Ana Fiandor, Santiago Quirce, Teresa Caballero
Journal: Journal of Allergy and Clinical Immunology (2016)
PWE-036 Does newer generations of narrow band imaging quantitatively improve contrast enhancement of endoscopic images?
Authors: N Mohammed, E Telakis, J Ariyarathnam, V Subramanian
Journal: Gut (2015)

<h3>Introduction</h3> Narrow band imaging (NBI) utilises optical filters to enhance the visibility of fine mucosal microvasculature. Wavelengths of light used in NBI are shorter (between 415–540 nm) corresponding to the wavelengths most intensely absorbed by haemoglobin. We aimed to quantitatively compare the effect of improvement in contrast enhancement using NBI among various series of Olympus endoscopes (240, 260 and 290 series) using serial dilutions of haemoglobin. <h3>Method</h3> We compared the visibility of human blood diluted with increasing concentrations (from ½ to 1/2<sup>23</sup>) of distilled water in a 24 well transparent plastic plate. Still images of the wells (overview and individual) were captured using GIF Q240 and GIF H260 endoscopes with a LUCERA spectrum CV260 processor (Olympus, Keymed, UK) and GIF H290 endoscope with an ELITE CV 290 processor (Olympus, Keymed UK) with white light and NBI. Images were independently analysed by three groups of endoscopists for the presence of blood; endoscopists with experience in NBI use (NBI-experienced), endoscopists with no former NBI experience but who have obtained accreditation by Joint Advisory Group (JAG) for diagnostic endoscopies (NBI-Naive) and doctors with no prior endoscopy experience (novices). Inter-rater agreement was assessed using Kappa statistics. The median visible dilution was defined as the limit of visibility for the presence of haemoglobin in the overview image. <h3>Results</h3> 45 participants (15 each of NBI-experienced, NBI-naïve and novices) completed the study. With conventional white light the median dilution at which all 3 groups noted the presence of haemoglobin was 1/2<sup>15 </sup>using all three generations of endoscopes. This improved using NBI to 1/2<sup>17</sup>for GIF Q240, 1/2<sup>19</sup>for GIF H260 and 1/2 <sup>20</sup>for GIF H290 series of endoscopes. The kappa values for inter-rater agreement was substantial for all 3 generations of endoscopes using conventional white light (κ &gt;0.7) while it was only moderate to fair for all 3 generations of NBI (κ &gt;0.5). <h3>Conclusion</h3> NBI more effectively enhanced the contrast of diluted blood compared to conventional white light. These differences improved with successive generations of NBI but not with conventional white light. Inter-rater agreement was fair for NBI, but substantial for conventional white light. Effective training and more objective criteria for the presence of blood could help improve inter-observer agreement. Studies are needed to assess the clinical utility of newer generation NBI in the detection of early neoplasia and assessment of inflammation. <h3>Disclosure of interest</h3> None Declared.
Activation of the transcription factor EB rescues lysosomal abnormalities in cystinotic kidney cells
Authors: Laura R. Rega, Elena Polishchuk, Sandro Montefusco, Gennaro Napolitano, Giulia Tozzi, Jinzhong Zhang, Francesco Bellomo, Anna Taranta, Anna Pastore, Roman Polishchuk, Fiorella Piemonte, Diego L. Medina, Sergio D. Catz, Andrea Ballabio, Francesco Emma
Journal: Kidney International (2016)
Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma-chain) by normal and malignant myeloid cells
Authors: RR Schumann, T Nakarai, HJ Gruss, MA Brach, U von Arnim, C Kirschning, L Karawajew, WD Ludwig, JC Renauld, J Ritz, F Herrmann
Journal: Blood (1996)
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion
Authors: J P Stevenson, D DeMaria, J Sludden, S B Kaye, L Paz-Ares, L B Grochow, A McDonald, K Selinger, P Wissel, P J O'Dwyer, C Twelves
Journal: Annals of Oncology (1999)

Preclinical results support a prolonged schedule of administration for topoisomerase I inhibitors, and we have previously demonstrated the safety and activity of the novel water-soluble topoisomerase I inhibitor GG211 when given as a 72-hour continuous infusion to cancer patients.In a three-center international phase I trial, 38 patients received GG211 doses from 0.3 to 0.5 mg/m2/day by continuous intravenous infusions for seven, 14, and 21 days. Patients' median performance status was 1; nearly half had colorectal cancer, and 35 patients had prior chemotherapy.The first patient cohort received 0.3 mg/m2/day for seven days with no significant toxicities. Subsequent cohorts received continuous infusions for 14 and 21 days at this dose level with only mild myelosuppression noted. Dose-escalation on the 21-day schedule was then performed. No dose-limiting toxicity occurred at the 0.4 mg/m2/day dose level. Thrombocytopenia was dose-limiting with 0.5 mg/m2/day dosing but was not cumulative. Other grade 3 4 toxicities included neutropenia, nausea, vomiting, diarrhea, and fatigue. Partial responses occurred with 21-day infusion in two patients with breast and ovarian cancer at the 0.3 and 0.4 mg/m2/day dose levels, respectively. Mean GG211 lactone Css ranged from 0.17 to 0.64 ng/ml.The maximum tolerated dose of GG211 administered as a 21-day continuous infusion is 0.4 mg/m2/day with antitumor activity noted at tolerable doses.
Neoadjuvant chemotherapy (NCT) in 466 patients for operable breast cancer: Predictive factors for pathological response.
Authors: C. Abrial, X. Durando, E. Thivat, E. Planchat, I. Raoelfils, M. Mouret-Reynier, P. Gimbergues, I. Van Praagh-Doreau, P. J. Chollet, F. Penault-Llorca
Journal: Journal of Clinical Oncology (2010)

648 Background: In a new database harbouringthe patients of several prospective phase II neoadjuvant trials (fec 50-100, net, tncf, taxotere/tncf, taxotere alone), the predictive value of tumour factors (SBR grade, RH, Her2, Ki-67 and cycline D1) was studied in 466 women with stage II-III operable breast cancer treated between 1991 and 2006. Methods: Median age of the patients was 48 years [27-76]. Median diameter of the invasive tumour was 40 mm [10-130]. 382 (82%) patients had a canalar, 57 (12.2%) a lobular, 14 (3%) a mixed or invasive carcinoma, 3 (0.6%) neoplasic cells only and 10 (2.2%) another carcinoma. Before chemotherapy, 32.8% were grade III SBR, 60% were RH+ and 10% were Her2+. For 36% of the tumours, the Ki-67 was ≤ 20% and for 16% of the tumours, the cyclin D1 was ≤ 20%. The median number of NCT courses was 6 [1-8] followed by a surgery for 98%, a radiotherapy for 93%, an adjuvant chemotherapy (20%) and/or a hormonotherapy (56%). Results: Overall response rate was 71% (17% complete). The complete pathological response (pCR) rate was 16.7% according to Chevallier's classification. On 455 patients operated, 324 (71%) had a conservative surgery. On 390 patients with an axillary dissection, 195 (50%) had involved nodes (median number :2 [1-20]). After a median follow-up of 121 months, DFS and actuarial survival at 120 months were 61.9% and 69.7%, respectively. Concerning the predictive value of the tumour factors, the pCR according to Chevallier's classification was threefold more frequent for Her-2-positive patients (p=1.7.10−3) and for RH negative patients (p=10−7) ; and elevenfold more frequent for SBR III patients (p=5.4.10− 7). Moreover, the pCR was twofold more frequent when Ki-67 was > 20% (p=0.012). There was no significant correlation between the cyclin D1 and the pCR. Using a multivariate analysis, these four factors remain predictive in the following order (from stongest to weakest): RH, Her2, SBR grade and Ki-67. Conclusions: SBR grade, RH, Her2 and Ki-67 were strong predictive factors of the pathological complete response. No significant financial relationships to disclose.
Femoral and Carotid Subclinical Atherosclerosis Association With Risk Factors and Coronary Calcium
Authors: Martín Laclaustra, José A. Casasnovas, Antonio Fernández-Ortiz, Valentin Fuster, Monserrat León-Latre, Luis J. Jiménez-Borreguero, Miguel Pocovi, Yamilee Hurtado-Roca, José M. Ordovas, Estibaliz Jarauta, Eliseo Guallar, Borja Ibañez, Fernando Civeira
Journal: Journal of the American College of Cardiology (2016)
The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer
Authors: Jennifer A. Ligibel, Eric P. Winer
Journal: Journal of the National Comprehensive Cancer Network (2003)

Adjuvant hormonal therapy has been shown to decrease the risk of breast cancer recurrence and overall mortality in patients with hormone receptor-positive breast cancer. Tamoxifen has been used in this setting for many years, both in premenopausal and postmenopausal patients. Tamoxifen is not devoid of toxicity, and attempts have been made to develop newer hormonal agents with better efficacy and less toxicity. The aromatase inhibitors have shown equivalent or superior efficacy to tamoxifen in the treatment of metastatic breast cancer, and efforts are underway to determine the role of these agents in early breast cancer. The ATAC trial recently showed that use of the third-generation aromatase inhibitor anastrozole in the adjuvant setting led to a modest improvement in relapse-free survival as compared with tamoxifen. Patients treated with anastrozole were also less likely to develop uterine cancer or experience a thromboembolic event. However, patients treated with anastrozole were more likely than those treated with tamoxifen to suffer a fracture or other musculosketal problem. An ASCO technology assessment panel reviewed the relevant data and issued a consensus statement regarding the use of aromatase inhibitors in the adjuvant setting. In general, the panel favored the continued use of tamoxifen as adjuvant hormonal therapy for most postmenopausal women. Within the next few years, further data from the ATAC trial and from other trials of aromatase inhibitors in the adjuvant setting should be available to guide treatment recommendations for this patient population.
Long-Acting Reversible Contraception and Condom Use
Authors: Julia Potter, Karen Soren
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Abstract 16946: The Association of Clinical Indication for Exercise Stress Testing With All-Cause Mortality
Authors: Joonseok Kim, Mouaz Al-Mallah, Seamus Whelton, Haitham M Ahmed, Stephen P Juraschek, Yichen Zhong, Khurram Nasir, Roger S Blumenthal, John Schairer, Steve J Keteyian, Michael J Blaha
Journal: Circulation (2013)

Background: Little is known about the association between the clinical indication for stress testing and all-cause mortality and the impact of exercise capacity on this relationship. Method: We stu...
LO7 : A single subcutaneous dose of 2mg/kg or 4mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against MIR-122, results in significant viral load reductions in chronic hepatitis C patients
Authors: M. Van Der Ree, M.L. de Vree, F. Stelma, S. Willemse, M. van der Valk, S. Rietdijk, R. Molenkamp, J. Schinkel, S. Hadi, M. Harbers, A. van Vliet, J. Udo de Haes, P. Grint, S. Neben, N. Gibson, H.W. Reesink
Journal: Journal of Hepatology (2015)
People with autism die 16 years earlier on average, says charity
Authors: Nigel Hawkes
Journal: BMJ (2016)

People with autism tend to die decades younger than the rest of the population, and more needs doing to understand the problem’s causes and to find potential solutions, says a new report from the charity Autistica.

Autistica’s report,1 drawing on recently published research in Sweden, said that people with autism die 16 years sooner on average than they otherwise would, and those whose autism is combined with intellectual disability die 30 years sooner.

Death comes earlier to autistic people, whatever the proximate cause. But epilepsy, which is diagnosed in 20-40% of autistic people, is a major cause of death, especially in those whose autism is severe and combined with learning difficulties. Among those who …
Prediction Of Second Generation Tyrosine Kinase Inhibitors Response After Imatinib Failure: The Value Of The Hammersmith Prediction Score
Authors: Franck E. Nicolini, Philippe Rousselot, Stephane Giraudier, Gabriel Etienne, Hyacinthe Johnson-Ansah, Lydia Roy, Pascale Cony-Makhoul, Yann Guillermin, Mohamad Sobh, Pierre Marie, Driss Kamar, Hesham Mohamed, Denis Caillot, Delphine Rea
Journal: Blood (2013)
Regression discontinuity designs in healthcare research
Authors: Atheendar S Venkataramani, Jacob Bor, Anupam B Jena
Journal: BMJ (2016)

Clinical decisions are often driven by decision rules premised around specific thresholds. Specific laboratory measurements, dates, or policy eligibility criteria create cut-offs at which people become eligible for certain treatments or health services. The regression discontinuity design is a statistical approach that utilizes threshold based decision making to derive compelling causal estimates of different interventions. In this review, we argue that regression discontinuity is underutilized in healthcare research despite the ubiquity of threshold based decision making as well as the design’s simplicity and transparency. Moreover, regression discontinuity provides evidence of “real world” therapeutic and policy effects, circumventing a major limitation of randomized controlled trials. We discuss the implementation, strengths, and weaknesses of regression discontinuity and review several examples from clinical medicine, public health, and health policy. We conclude by discussing the wide array of open research questions for which regression discontinuity stands to provide meaningful insights to clinicians and policymakers
Abstract 11759: Poldip 2 Regulates Adhesion and Spreading of Vascular Smooth Muscle Cells Through Its Interaction With Kindlin-2 and Talin
Authors: Mazen K Khalil, Bernard Lassegue, Daniel McGrail, S Raju Datla, Alejandra San Martin, Michelle Dawson, Kathy Griendling
Journal: Circulation (2012)

Vascular smooth muscle cell (VSMC) migration is a key step in atherosclerosis. Cell migration depends on adhesion to a substrate, extension of lamellipodia, and formation of focal adhesions (FA). P...